Molecular insights into NF2/Merlin tumor suppressor function  by Cooper, Jonathan & Giancotti, Filippo G.
FEBS Letters 588 (2014) 2743–2752journal homepage: www.FEBSLetters .orgReviewMolecular insights into NF2/Merlin tumor suppressor functionhttp://dx.doi.org/10.1016/j.febslet.2014.04.001
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
⇑ Fax: +1 212 639 3917 (F.G. Giancotti).
E-mail addresses: cooperj1@mskcc.org (J. Cooper), F-Giancotti@ski.mskcc.org
(F.G. Giancotti).Jonathan Cooper ⇑, Filippo G. Giancotti ⇑
Cell Biology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, United States
a r t i c l e i n f o a b s t r a c tArticle history:
Received 26 February 2014
Revised 1 April 2014
Accepted 2 April 2014
Available online 12 April 2014
Edited by Shairaz Baksh, Giovanni Blandino
and Wilhelm Just
Keywords:
Merlin
Neurofibromatosis Type 2
Hippo signaling pathway
Contact inhibition
DDB1 and Cul4-Associated Factor 1
CRL4 E3 ubiquitin ligaseThe FERM domain protein Merlin, encoded by the NF2 tumor suppressor gene, regulates cell prolif-
eration in response to adhesive signaling. The growth inhibitory function of Merlin is induced by
intercellular adhesion and inactivated by joint integrin/receptor tyrosine kinase signaling. Merlin
contributes to the formation of cell junctions in polarized tissues, activates anti-mitogenic signaling
at tight-junctions, and inhibits oncogenic gene expression. Thus, inactivation of Merlin causes
uncontrolled mitogenic signaling and tumorigenesis. Merlin’s predominant tumor suppressive
functions are attributable to its control of oncogenic gene expression through regulation of Hippo
signaling. Notably, Merlin translocates to the nucleus where it directly inhibits the CRL4DCAF1 E3
ubiquitin ligase, thereby suppressing inhibition of the Lats kinases. A dichotomy in NF2 function
has emerged whereby Merlin acts at the cell cortex to organize cell junctions and propagate anti-
mitogenic signaling, whereas it inhibits oncogenic gene expression through the inhibition of
CRL4DCAF1 and activation of Hippo signaling. The biochemical events underlying Merlin’s normal
function and tumor suppressive activity will be discussed in this Review, with emphasis on recent
discoveries that have greatly inﬂuenced our understanding of Merlin biology.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ability of normal cells to survive and proliferate is dictated
by environmental cues, including intercellular and matrix
adhesions as well as the presence of growth factors. Normal cells
undergo growth arrest when detached from the extracellular ma-
trix or when they come into contact with adjacent cells and form
intercellular junctions [1]. Neoplastic cells evade contact inhibition
of proliferation, which leads to the disruption of tissue organiza-
tion – a distinguishing event in cancer [2]. The NF2 (Neurofibroma-
tosis Type 2) tumor suppressor gene encodes the FERM (4.1
protein/Ezrin/Radixin/Moesin) domain protein Merlin, which is
coordinately regulated by intercellular adhesion and attachment
to the extracellular matrix [3–7]. Cadherin engagement inactivates
PAK, causing an accumulation of the active, dephosphorylated
form of Merlin. Notably, since integrin attachment to the extracel-
lular matrix activates PAK, Merlin can therefore be regulated
independently of contact-mediated signaling events [7].
Neuroﬁbromatosis type 2 patients carry a single mutated NF2
allele and develop a highly speciﬁc subset of central and periphe-
ral nervous system tumors. NF2-associated tumors include
schwannomas, meningiomas, and ependymomas, which arise fromthe Schwann cells comprising the myelin sheath surrounding sen-
sory and motor neurons, arachnoid cap cells within the arachnoid
villi in the meninges, and ependymal cells lining the CSF-ﬁlled ven-
tricles of the brain and central spinal canal, respectively. In addi-
tion to the autosomal dominant NF2 disorder, non-germline
Merlin deﬁciency is a driving force in sporadic occurrences of
nearly all vestibular schwannomas, a majority of meningiomas,
and a notable fraction of ependymomas. Moreover, Merlin was
found to be inactivated in a large proportion of malignant mesot-
heliomas [8,9] and to a lesser extent in other solid tumors [10–13].
Due in large part to Merlin’s high sequence homology to the
ERM (Ezrin/Radixin/Moesin) family of cytoskeletal linker proteins,
it was widely assumed that Merlin suppresses mitogenic signaling
at the cell cortex to mediate contact inhibition and tumor suppres-
sion [14]. Active Merlin suppresses Rac-PAK signaling [7,15–17],
restrains activation of mTORC1 independently of Akt [18,19],
inhibits PI3K-Akt and FAK-Src signaling [20,21], and negatively
regulates the EGFR-Ras-ERK pathway [22,23]. However, the mech-
anisms by which Merlin inhibits these pathways remain unclear,
and furthermore, the relative contribution of these pro-mitogenic
signals to various Merlin-deﬁcient malignancies is unknown. Inter-
estingly, Merlin activates the Hippo tumor suppressor pathway to
suppress the transcriptional coactivators YAP/TAZ in mammals or
the Drosophila ortholog Yorkie, revealing a conserved role for
Merlin in regulation of organ size, stem cell behavior, and cell pro-
liferation [24–26]. Notably, few germline or somatic mutations of
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mors – the exception being Merlin, which remains as one of the
only bona ﬁde tumor suppressors in the Hippo pathway.
Merlin’s upstream regulation has been extensively
characterized, and recently reported models of regulation and
post-translational modiﬁcation will be highlighted in this Review.
Post-translational modiﬁcation of Merlin is vitally important to its
conversion between dormant and growth-inhibitory states, where
the dephosphorylated and more open state is now considered to be
active in contact inhibition and tumor suppression [27]. However,
without crystallographic analyses of full-length Merlin in both its
active and inactive conformations, structural inferences drawn
from biochemical experiments must be approached with caution.
Apropos of the myriad upstream signals and modiﬁcations affect-
ing Merlin, the downstream biochemical functions of Merlin have
been the subject of intensive research for two decades, yet a con-
sensus mechanism for Merlin’s function in normal tissues has not
been reached. It is becoming apparent that Merlin functions
primarily in two branches – contact inhibition of proliferation
and tumor suppression. Although these branches are naturally
intertwined, the distinct locations of Merlin function and respec-
tive interactors in those subcellular compartments lend credence
to a concept of a bimodal function.
Recent studies among the ever-increasing breadth of NF2 litera-
ture have revealed important high-afﬁnity interactors governing
Merlin’s biochemical function. Notably, Merlin regulates tight
junction-associated Angiomotin to inhibit Rac signaling [28], and
nuclear-localized Merlin inhibits the CRL4DCAF1 E3 ubiquitin ligaseFERM 
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Merlin in a more closed, inactive form.to suppress oncogenic gene expression [29]. Moreover, Merlin’s
regulation of YAP/TAZ is a burgeoning and highly provocative ﬁeld
due to the multifarious roles of Hippo signaling in organ growth,
stem cell maintenance, and cancer. Recent studies have also shed
light on Merlin’s conformational changes that regulate its intramo-
lecular associations and downstream signaling, providing funda-
mental insight into Merlin’s regulation and biochemical function.
In this Review, we will explore Merlin’s rich biochemical back-
ground and examine new insights that are shaping our understand-
ing of Merlin’s role in normal biology and how its loss leads to the
deregulation of a multitude of signaling pathways leading to
tumorigenesis.
2. The NF2 gene
NF2 maps to the long arm of chromosome 22 and encodes two
Merlin isoforms. The longer, dominant Merlin isoform 1 (Merlin-1
or Merlin), has an extended carboxy-terminal tail that is encoded
by exon 17 (Fig. 1A). Merlin isoform 2 (Merlin-2), on the other
hand, contains the alternatively spliced exon 16 which ends in a
stop codon, encoding 11 unique residues following amino acid
579 as compared to Merlin-1 [10]. Notably, Merlin-2 lacks
carboxy-terminal residues required for intramolecular binding be-
tween the amino-terminal FERM domain and the carboxy-terminal
tail, possibly leading to a constitutively open conformation [30,31].
Recent studies have found that Merlin-2 inhibits cell proliferation
and attenuates downstream mitogenic signaling to the same
extent as Merlin-1 [27,32].Coiled-Coil C-term 
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The biochemical functions of Merlin are imparted by three
mechanisms – post-translational modiﬁcation, localization, and
interaction with downstream effectors. Merlin is composed of a
globular amino-terminal FERM domain and a carboxy-terminal
hydrophilic tail joined by a ﬂexible coiled-coil segment, displaying
structural resemblance to the FERM domain-containing ERM pro-
teins (Fig. 1A) [33,34]. This resemblance is most apparent in the
ﬁrst 300 residues of Merlin’s FERM domain, which share 65% se-
quence identity with canonical ERMs. However, Merlin has several
notable differences in its primary sequence that distinguish it in
form and function from its ERM counterparts. Merlin’s amino-ter-
minus contains a 7-residue conserved Blue box motif and 17 un-
ique amino-terminal residues [35,36]. Importantly, Merlin lacks a
canonical actin-binding motif that is otherwise conserved among
ERMs and paramount to their function at the cortical cytoskeleton
[14].
A central mechanism in Merlin and ERM function is the forma-
tion of homo- and heterotypic interactions that regulate their
activity. The majority of ERMs within cells are held in a dormant
state imparted by an intramolecular association between the FERM
domain and the C-terminal tail [37–39]. Disruption of this associ-
ation and subsequent activation is achieved by phosphorylation
of an ERM C-terminal threonine residue by Rho kinase. Active
ERMs bind to cytoplasmic domains of cell-adhesion receptors such
as CD44 and ICAM via their FERM domains while their C-termini
interact with and regulate the cortical actin cytoskeleton [40,41].
Furthermore, once opened, active ERM proteins may form interac-
tions amongst themselves and with Merlin [37]. Merlin’s intramo-
lecular associations and subsequent activation states have been a
subject of intensive study for nearly 20 years [27,30,31,38,42–
44], yet a consensus model to explain the relationship between
its phosphorylation and interdomain binding in the context of
seemingly contrary genetic evidence has only recently been
uncovered.
It is well established that Merlin switches from an active state
to an inactive state by phosphorylation at serine 518 (Fig. 1B)
[45]. Phospho-mimetic (S518D) or phospho-deﬁcient (S518A) per-
mutations strongly correlate with Merlin’s growth-permissive or
growth-inhibitory functions, respectively [27,29,46]. Essentially,
serine 518 phosphorylation acts as a binary switch in which
dephosphorylated Merlin functions in adhesion signaling while
phosphorylated Merlin remains dormant, although studies within
the last ﬁve years have shown this to be an oversimpliﬁed interpre-
tation. Several lines of evidence suggest that Merlin exists in multi-
ple states that vary between ‘‘fully open’’ and ‘‘fully closed’’ forms
which are regulated primarily by S518 phosphorylation, and more-
over, FRET studies reveal that Merlin’s FERM domain and carboxy-
terminus are constitutively held in close proximity, undergoing
only subtle changes upon post-translational modiﬁcation [27,47].
A classic study found that Merlin-2 – which lacks the carboxy-ter-
minal residues necessary for intramolecular interaction – is unable
to function in contact inhibition or tumor suppression [30]. This
observation led to a hypothesis that was held for over a decade
positing that dephosphorylated and active Merlin functions in a
closed conformation.
Recently, two independent laboratories found that Merlin-2
suppresses growth in mammalian cell lines, suggesting that inter-
domain binding is dispensable for Merlin’s adhesion signaling
[27,32]. Through comprehensive biochemical investigation,
Anthony Bretscher’s group reported that phosphorylated Merlin
displays higher interdomain binding and that Merlin therefore
inhibits cell growth in its open state [27]. These results are under-
scored by the observation that a stably closed Merlin mutant doesnot suppress cell growth, whereas Merlin-2 and the S518A mutant
– which are both defective in interdomain binding and therefore
more open – suppress growth to the same extent as wild-typeMer-
lin. Cumulatively, these results reveal that S518 phosphorylation
or mutations that cause Merlin to becomemore closed result in de-
creased growth inhibition, whereas more open forms of Merlin –
those that are increasingly defective in interdomain binding – are
more active in growth inhibition. This ﬁnding contributes greatly
to a consensus of Merlin structure and function as it relates to nor-
mal biology and tumor suppression, resolving a decade-old schism
between biochemical observations and in vivo genetic studies.
Biochemical studies have provided essential insight into Mer-
lin’s conformational changes and resulting activation, which are
now largely corroborated by genetic data. Most patient-derived
truncations and a vast majority of non-truncating mutations occur
within the FERM domain (Fig. 1A), lending credence to its quintes-
sential role in anti-mitogenic signaling and tumor suppression
[48]. Initially discovered in Drosophila, the ‘‘Blue box motif’’ is a
conserved region within the FERM subdomain F2 corresponding
to residues 177–183 in human Merlin. Substitution of these resi-
dues with alanines imparts loss of contact inhibition and promotes
tumorigenesis in NIH-3T3 cells [49]. Mutations in the Blue box act
in a dominant negative manner in both Drosophila and mammals,
displaying the importance of the FERM domain in Merlin’s tumor
suppressive function. As compared to the FERM domain, mutations
are scarce in Merlin’s carboxy-terminal tail and are dramatically
reduced in the central a-helical domain, again implying that Mer-
lin’s downstream tumor suppressive functions are imposed by the
FERM domain (Fig. 1A) [48]. Notably, replacement of Merlin’s F2
subdomain with that of the ERM protein Ezrin abolishes its growth
suppressive activity, while individual or combined replacement of
subdomains F1 and F3 do not affect proliferation [32]. These results
imply that subdomain F2 of Merlin’s FERM domain is largely
responsible for Merlin’s growth inhibitory effects. Truncating
mutations correlate with increased NF2 severity and predominate
among NF2 patients, while missense mutations – although more
rare and generally less severe – allow for a more systematic inter-
pretation of Merlin’s biochemical role in tumor suppression. Mer-
lin’s FERM domain interacts directly with the CRL4DCAF1 E3
ubiquitin ligase, inhibiting its ubiquitination activity and down-
stream oncogenic signaling. Multiple patient-derived missense
mutants, including those mapping to subdomain F2, are defective
in CRL4DCAF1 interaction, despite the fact that some of these muta-
tions were predicted to cause little structural perturbation [29,34].
Recent biochemical insights combined with more than a decade
of patient-derived genetic data provide crucial insight into Merlin’s
normal biochemical function and role in tumor suppression. Mer-
lin’s a-helical domain and carboxy-terminus function in maintain-
ing Merlin in an inactive conformation during normal biological
function, and may further be necessary for functions underneath
the cell cortex in the organization of cell junctions and in contact
inhibition. However, while interdomain binding is an important
part of Merlin’s regulation and normal cellular functions, the over-
all structure and speciﬁc protein-interacting domains within Mer-
lin’s amino-terminal FERM domain are essential for contact
inhibition and tumor suppression.
4. Post-translational modiﬁcation of Merlin
Merlin is regulated by multiple post-translational modiﬁcations
downstream of an ever-expanding array of intracellular and extra-
cellular cues. Receptor tyrosine kinases and integrins relay pro-
mitogenic signals by activating CDC42 and Rac, which in turn acti-
vate p21-activated kinase (PAK) (Fig. 1B). Activated PAK directly
phosphorylates Merlin at serine 518, leading to an increase in
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Fig. 2. (A) Merlin activates the Hippo pathway to suppress YAP/TAZ through
regulation of core kinase components at the plasma membrane, through inhibition
of the CRL4DCAF1 E3 ubiquitin ligase in the nucleus, and by regulating cell junction-
associated proteins that modulate Hippo signaling. (1) At adherens junctions, E-
cadheren promotes Hippo signaling while a-catenin sequesters 14-3-3 protein-
bound YAP. Merlin interacts with a-catenin at maturing adherens junctions in skin
epithelium, plausibly inﬂuencing Hippo signaling at this subcellular compartment.
(2) At the plasma membrane, Merlin recruits the Lats kinases and coordinates their
activation by Mst1, driving phosphorylation and inhibition of YAP/TAZ. (3) The
Crumbs homolog (CRB) complex recruits Angiomotin (AMOT), which directly binds
Hippo pathway components. AMOT serves as a scaffold for Mst1/2 and Lats1/2
activation and also directly binds and inhibits YAP. Conversely, the p180 isoform of
AMOT promotes YAP function in the nucleus. Merlin interacts with AMOT at tight
junctions to suppress Rac activity, however, it remains to be determined how
Merlin inﬂuences Angiomotin’s inhibition of YAP at tight junctions or YAP-
activating functions in the nucleus. (4) Dephosphorylated Merlin translocates to
the nucleus and inhibits CRL4DCAF1, preventing this E3 ligase from ubiquitinating
and inhibiting Lats1/2. These core Hippo pathway components, activated by an
upstream kinase, phosphorylate and inactivate YAP/TAZ. (B) Merlin’s regulation of
CRL4DCAF1 impinges on multiple downstream epigenetic mechanisms and blocks
oncogenic gene expression. In contact inhibited cells, active Merlin translocates to
the nucleus where it binds to and inhibits the CRL4DCAF1 E3 ubiquitin ligase. Active
or dysregulated CRL4DCAF1 induces an oncogenic gene expression program by
promoting downstream Hippo pathway targets via inhibition of the Lats1/2 kinases
and through modulation of epigenetic modiﬁers and transcription factors.
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subsequent inactivation, presumably through masking of protein-
interacting domains on the FERM domain which are necessary
for downstream signaling or occlusion of a nuclear localization sig-
nal [29,33]. Since Merlin has a long half-life within cells, it is a
compelling hypothesis that phosphatases exist to dephosphorylate
Merlin at serine 518 and dynamically control levels of the dephos-
phorylated active form. MYPT1-PP1d (MYPT1) is a phosphatase
that was shown to dephosphorylate Merlin [22] (Fig. 1B), and
recent evidence revealed that it may be inhibited by integrin-
linked kinase (ILK) [50]. It remains to be determined whether
MYPT1-mediated Merlin activation via dephosphorylation is a
major mechanism in NF2-mediated tumor suppression or whether
nascent and dephosphorylated Merlin largely functions in this
capacity.
The phosphorylation status of serine 518 drives Merlin’s activa-
tion cycle, although other modiﬁcations modulate Merlin’s confor-
mation and downstream biochemical functions. Phospho-peptide
mapping and band-shift experiments revealed that Merlin is phos-
phorylated at multiple sites and that serine 518 phosphorylation
may be necessary for subsequent phosphorylation at other residues
[51,52]. In addition to PAK-mediated phosphorylation, PKA was
shown to independently phosphorylate Merlin at serine 518 and
serine 10, the latter modiﬁcation affecting the actin cytoskeleton
[53,54]. Merlin’s phosphoregulation by PKA may be an important
mechanism in cells which are sensitive to the cyclic AMP-PKA sig-
naling axis, including the pathogenically relevant Schwann cells
[55]. AKT phosphorylates Merlin at two additional sites – threonine
230 and serine 315 – and this phosphorylation causes decreased
interdomain binding, intermolecular binding to phosphoinositides
and PIKE-L (a GTPase that enhances PI3K activity), and ubiquitina-
tion [56]. The observation that AKT-mediated phosphorylation
blocks Merlin’s interaction with PIKE-L supports an inhibitory role
for this interaction [20,56]. This ﬁnding also raises the possibility
that constitutive activation of the PI3K-Akt pathway resulting from
PTEN loss or activating PI3K mutations would lead to Merlin inacti-
vation, imparting a PI3K feed-forward mechanism. However, spec-
ulation that Merlin is inactivated by decreased interdomain
binding conﬂicts with the recent observations that the open form
of Merlin is active [27,32]. Moreover, the importance of the ubiqui-
tin–proteasome system in Merlin’s degradation is debatable, as
cycloheximide chase experiments revealed that Merlin has a half-
life exceeding 24 h [29], although this does not rule out other ubiq-
uitination-mediated effects on Merlin function. Akt- and PAK-med-
iated phosphorylation of Merlin was recently shown to promote its
sumoylation – an ubiquitin-like modiﬁcation – which was found to
affect Merlin’s subcellular localization, interdomain binding,
and growth-inhibitory activity [57]. However, the requirement
for sumoylation in Merlin’s normal function and in tumor suppres-
sion remains incompletely understood since serine 518 phosphory-
lation, which renders Merlin inactive, appears to promote its
sumoylation.
5. Merlin localization and function
5.1. Functions at the plasma membrane, cell cortex, and cytoskeleton
As cells become conﬂuent, Merlin interacts with membrane-
associated proteins where it regulates the formation of membrane
domains [58]. Merlin’s organization of intercellular contacts is cen-
tral to its normal function in contact inhibition, which is disrupted
in Merlin-deﬁcient tissues [59]. Indeed, Merlin was initially inter-
preted as functioning at the cell cortex due to its homology to
ERM proteins and its localization by immunostaining [60]. This
notion was supported in Drosophila by the observation that nascentMerlin is recruited to the plasmamembrane [36,61]. These observa-
tions were corroborated by Merlin’s role in the establishment of
adherens junctions in conﬂuent cells and localization in lamellipo-
dia andmembrane rufﬂes [5,7,62–64]. Merlin interacts with a num-
ber of proteins that are localized at or underneath the plasma
membrane, including other ERMs, NHERF, the intracellular domain
of CD44, a-catenin atmaturing adherens junctions, and Angiomotin
at tight junctions [6,28,59,60,65].
Table 1
Patient-derived NF2 mutations abrogate Merlin’s regulation of CRL4DCAF1. The
indicated patient-derived missense and truncation mutants are defective in nuclear
translocation, direct binding to CRL4DCAF1, suppression of CRL4DCAF1-mediated
ubiquitination, or a combination of these mechanisms. As a result, the NF2-derived
missense mutants are unable to interact with CRL4DCAF1 in vivo, permitting the
dysregulated ligase to promote tumorigenesis. NT, not tested. Data were obtained
from [29].
Patient-derived
Merlin mutation
Biochemical defect (relative to wild-type)
Nuclear
exclusion
Reduced In vitro
DCAF1 binding
Reduced DCAF1
ligase inhibition
L46R + + NT
F62S  + NT
L64P + + NT
L141P + + NT
A211D +  NT
E270G  + NT
466X NT NT +
341X   +
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catenin and promotes its binding to Par3, aiding in the maturation
of adherens junctions (Fig. 2A) [59]. This is consistent with the dis-
ruption of adherens junctions in Merlin-deﬁcient primary ﬁbro-
blasts and keratinocytes [5]. Interestingly, a-catenin can bind to
14-3-3 protein, which sequesters phosphorylated YAP in the cyto-
plasm and suppresses YAP-mediated transcription [66,67]. More-
over, it was recently discovered that a-catenin interacts with the
APC tumor suppressor to promote the ubiquitination and degrada-
tion of b-catenin as well as repression of Wnt target genes in the
nucleus [68]. Since Merlin’s interaction with a-catenin and its role
in junction formation was exclusively studied in skin and ﬁbro-
blasts, it is difﬁcult to put this mechanism in the context of NF2
pathogenesis and other Merlin-deﬁcient malignancies. It will be
of great interest to see whether Merlin’s interaction with a-catenin
leads to the suppression of YAP- and b-catenin-mediated onco-
genic gene expression in pathogenically-relevant tissues.
Merlin interacts with the scaffold and signaling protein Angi-
omotin at mature tight junctions, regulating contact inhibition
and potentially tumor suppression (Fig. 2A) [28]. Angiomotin ex-
ists in two isoforms – both of which interact with Merlin – and
associate with tight junctions through interactions with Patj, Pals1,
and Mupp1 [69,70]. At assembled tight junctions, Merlin binds to
Angiomotin and displaces Rich – a GTPase Activating Protein for
Rac – thus suppressing Rac-PAK signaling [28]. Therefore, Merlin’s
inhibition of Rac at tight junctions promotes contact inhibition and
acts as a barrier to mitogenic signaling [7]. One major caveat to this
ﬁnding is that Angiomotin interacts not only with Merlin’s a-heli-
cal and carboxy-terminal domains, but also with phospho-deﬁ-
cient and phospho-mimetic Merlin mutants [28]. These results
strongly imply that Merlin binds to Angiomotin regardless of its
activation status, and therefore, independently of growth suppres-
sive stimuli. Further work is needed to fully understand the role of
Angiomotin in Merlin’s function in normal cells and in Merlin-deﬁ-
cient tumorigenesis.
A fraction of Merlin has been found to localize to cholesterol-
dependent membrane domains – which were interpreted as lipid
rafts – as a result of phosphoinositide binding [71,72]. In several
studies, active Merlin was shown to bind phosphoinositides,
although there is contradicting evidence as to whether this occurs
in Merlin’s active or inactive forms [72,73], raising uncertainty
over the relevance of this interaction to adhesion signaling. How-
ever, a Merlin mutant lacking residues necessary for phosphoinosi-
tide binding – K79, K80, K269, E270, K278, and K279 – was
signiﬁcantly defective in suppressing growth of Merlin-deﬁcient
cells [72]. This observation was supported by experiments con-
ﬁrming that the Merlin mutant retained normal folding. However,
the ability of the phosphoinositide-binding mutant to interact with
other proteins that were previously shown to mediate Merlin’s
function was not tested. Notably, mutation of Merlin E270 abol-
ishes interaction with CRL4DCAF1, which could explain the
growth-suppression defects of the phosphoinositide-binding
mutant [29]. Merlin’s phosphoinositide binding and potential
localization to lipid rafts requires further scrutiny to determine
its relevance both in normal biological function and in Merlin-
deﬁcient pathogenesis.
In addition to Merlin’s localization at the cortex and contact-
dependent membrane domains, Merlin functions in the cytoplasm
to control cytoskeletal dynamics and vesicular transport. Merlin
associates with actin and tubulin in the cytoplasm [32,74,75],
although Merlin’s association with the actin cytoskeleton is dis-
pensable for tumorigenesis [32,76]. Merlin migrates along micro-
tubules in a kinesin-1- and dynein-dependent manner [75], and
Merlin was recently found to slow the turnover of microtubules,
thus stabilizing them [77]. In addition, Merlin has been found to
promote microtubule-mediated anterograde transport of vesicles[78], which could function in promoting the transport of anti-mito-
genic biomolecules or regulating the availability of growth factors
at the plasma membrane. Merlin’s effects on the actin cytoskeleton
do not appear to be pathogenically relevant, and it remains to be
demonstrated whether regulation of microtubule dynamics is nec-
essary in Merlin-mediated contact inhibition and tumor suppres-
sion in vivo. Therefore, current models imply that Merlin largely
enforces contact inhibition and the organization of membrane do-
mains by acting at the plasma membrane or cortex, while Merlin’s
strongest tumor suppressive functions are enforced in another cel-
lular compartment.
5.2. Nuclear localization and inhibition of CRL4DCAF1
Dephosphorylated Merlin translocates to the nucleus where it
binds to and inhibits the CRL4DCAF1 E3 ubiquitin ligase (Fig. 2B)
[29], which was the ﬁrst identiﬁcation of a nuclear binding partner
for Merlin. Observation that the dephosphorylated form of Merlin
preferentially translocates to the nucleus while the phosphorylated
form is largely excluded is consistent with the long-standing
observation that Merlin suppresses tumorigenesis in its dephos-
phorylated form [27,29,32,49]. Moreover, several reports have
characterized Merlin’s localization in the nucleus, and Merlin mi-
grates towards the nucleus by microtubule-based transport in Dro-
sophila [57,75,79,80]. Although Merlin lacks a canonical nuclear
localization sequence, it contains a motif on its carboxy-terminus
that promotes nuclear export by the CRM1-exportin pathway
[80], and truncations that remove these residues show increased
nuclear localization [29,32]. Interestingly, the isolated FERM do-
main of Merlin is necessary and sufﬁcient for nuclear localization,
once again highlighting the importance of Merlin’s FERM domain
in its normal function (Table 1) [29]. Moreover, the dephosphoryl-
ated form of Merlin preferentially localizes to the nucleus in con-
ﬂuent and growth factor-deprived cells, when Merlin’s anti-
mitogenic effects would be most active [29]. As the phosphory-
lated, more closed form of Merlin is excluded from the nucleus,
interdomain binding imposed by S518 phosphorylation may oc-
clude the FERM domain residues necessary for nuclear transloca-
tion [27,29]. Since a large proportion of Merlin shuttles to the
nucleus in contact-inhibited cells, Merlin’s nuclear function –
particularly inhibition of the oncogenic CRL4DCAF1 ubiquitin ligase
– may be vital for growth suppression [29]. Indeed, multiple lines
of evidence suggest that Merlin suppresses tumorigenesis largely
through inhibition of CRL4DCAF1. Genetic epistasis experiments in
several cell lines – including pathogenically relevant human
schwannoma and mesothelioma cells – reveal that Merlin
mediates its tumor suppressive and anti-mitogenic effects through
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missense mutants are unable to interact with DCAF1 as a result
of nuclear localization defects, disruption of Merlin-DCAF1 bind-
ing, or a combination of these aberrations (Table 1) [29]. Under-
standing more about CRL4DCAF1 biology and its interaction with
Merlin and other binding partners is an important step in concep-
tualizing how Merlin’s inhibition of this E3 ligase is an important
stepping stone in the control of multiple pro-oncogenic signaling
pathways.
DCAF1 (DDB1 and Cul4-Associated Factor 1) was originally
identiﬁed as VprBp (Vpr-binding protein) – a cytoplasmic protein
that binds to the HIV-1 viral accessory protein Vpr [81,82], before
it was found to function as the substrate recognition subunit of the
CRL4DCAF1 E3 ubiquitin ligase [83]. Viral Vpr and the related Vpx
proteins promote HIV and SIV infection by functioning as adaptors
that bind to DCAF1 and usurp its recruitment of substrates to de-
grade proteins that normally suppress viral infectivity [84,85]. In
fact, viral subversion of E3 ubiquitin ligases occurs in a number
of human diseases [83,86–89]. SAMHD1 is a viral restriction factor
which functions in myeloid-lineage cells and resting CD4+ T-cells
by reducing the concentration of cellular dNTPs and thus inhibiting
the viral reverse transcriptase. In HIV-2 and SIV, Vpx binds to
DCAF1 and acts as an adaptor to co-opt the ubiquitin-conjugating
machinery to target and degrade SAMHD1 [90–95]. A recent land-
mark study found that Vpx binds the WD40 domain of DCAF1 to
produce a new surface that recruits SAMHD1, providing the ﬁrst
structural elucidation of lentiviral hijacking of the cell’s ubiqui-
tin–proteasome system [96]. These studies provide a starting point
to understand how CRL4DCAF1 binds its targets, and furthermore,
how Merlin may serve as an inhibitory pseudo-substrate (Fig. 3A).
Structural analysis of the DCAF1–Vpx–SAMHD1 complex re-
vealed that Vpx creates a new binding surface by enclosing a por-
tion of the DCAF1 WD40 domain. The WD40 domain of DCAF1,
near the carboxy-terminus, is a seven-bladed b-propeller that
forms an overall fan shape [96]. Residues within the WD40 domain
are necessary for interacting with DDB1 and therefore docking to
the CRL4 complex [83]. As Vpx-associated DCAF1 is able to recruit
SAMHD1 and mediate its ubiquitination [96], it is plausible that
DCAF1 uses portions of its WD40 domain to bind native targets.
A recent study found that DCAF1 can recruit mono-methylated
proteins using the hydrophobic pocket within its chromo domain,
which resides in the amino-terminal half of the protein [97]. In
addition to the role of CRL4DCAF1 in ubiquitination, DCAF1 has a
putative kinase domain near the amino-terminus which impartsActive CRL4DCAF1Merlin-bound CRL4DCAF1
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Fig. 3. (A) Active Merlin translocates to the nucleus and binds to the carboxy-
terminus of DCAF1, acting as a pseudo-substrate to block CRL4DCAF1 from recruiting
and ubiquitinating target proteins. Merlin’s inhibition of CRL4DCAF1 suppresses
oncogenic gene expression. (B) CRL4DCAF1 is an E3 ubiquitin ligase consisting of the
substrate-recruiting DCAF1 protein which is linked to the amino-terminal domain
of a cullin (Cul4A/B) backbone through DDB1, which is itself a large multi-domain
protein. Bound to the cullin carboxy-terminal domain, Rbx1 uses its RING domain
to recruit an ubiquitin-charged E2, which directs conjugation of ubiquitin to a
DCAF1-bound target protein.intrinsic kinase activity towards histone H2A to downregulate
anti-mitogenic genes [98]. Combined, these studies reveal that
DCAF1 can interact with multiple target proteins using several dis-
tinct regions spanning its primary sequence. However, without fur-
ther structural characterization of full-length DCAF1, it cannot be
ruled out that these domains are juxtaposed, and that one or more
protein-interacting regions act in a single multifunctional recruit-
ment domain.
DCAF1 was established as the substrate recognition component
of the CRL4DCAF1 E3 ligase (Fig. 3B) nearly ten years ago [83], and
several CRL4DCAF1 targets have been discovered. Vpr- and Vpx-
mediated targeting of SAMHD1 and the uracil DNA glycosylase
UNG2 direct these proteins to proteasomal degradation [91,99].
Moreover, it was found that CRL4DCAF1 is recruited by Vpr to acti-
vate the SLX4 complex, a structure-speciﬁc endonuclease whose
ectopic activation results in G2/M arrest and evasion of innate
immunity in HIV-infected cells [100]. Native DCAF1-binding pro-
teins include Merlin, the nuclear orphan receptor Rora, histones
H2A and H3, HDAC, the polarity protein Lgl, the lymphoid cell-spe-
ciﬁc V(D)J recombination protein RAG1, and the replication factor
Mcm10 [29,97,101–104]. Several of these proteins – particularly
the histones and HDAC – can broadly affect epigenetics, suggesting
that Merlin’s inhibition of CRL4DCAF1 can greatly alter gene expres-
sion. It was recently observed that CRL4DCAF1 interacts with and
promotes activation of TET proteins, a family of enzymes that con-
vert 5-methylcytosine to 5-hydroxymethylcytosine (5hmC) [105].
These conversions cause epigenetic modiﬁcations that regulate
DNA demethylation and therefore gene transcription, which were
shown to have dramatic effects during embryonic development
and tumorigenesis. Notably, loss of TET2 is a common occurrence
in myeloid leukemia and 5hmC reduction is a distinguishing fea-
ture of melanoma and is observed in a range of other solid tumors
[106]. However, the mechanism by which CRL4DCAF1 regulates TET
proteins – whether by ubiquitination or another modiﬁcation – is
currently unknown. Indeed, the mechanism by which CRL4DCAF1
modulates several bona ﬁde interactors remains elusive, and it is
unclear whether ubiquitination of these targets is necessary or suf-
ﬁcient for their regulation. Regardless, these ﬁndings suggest that
CRLDCAF1 can multifariously modulate epigenetics (Fig. 2B), and
its dysregulation following Merlin deﬁciency shifts cells towards
an oncogenic gene expression program. Indeed, Merlin expression
and DCAF1 knockdown in Merlin-deﬁcient cells reveal that Merlin
suppresses tumorigenesis largely through DCAF1 inhibition, pro-
viding further support that Merlin regulates oncogenic gene
expression through its inhibition of the CRL4DCAF1 E3 ubiquitin
ligase [29].
Merlin’s FERM domain binds the carboxy-terminal acidic tail of
DCAF1, which is outside of the WD40 domain [29]. Since the
DCAF1 acidic tail is adjacent to its WD40 domain in its primary se-
quence, it is possible that Merlin’s binding to the tail brings it in
close proximity to the binding surface of the WD40 propeller
(Fig. 3A). However, many possibilities exist to explain how Merlin
can reduce CRL4DCAF1 activity [29]; this is further complicated by
the multiple protein-interacting domains within DCAF1. A ground-
work explanation is that Merlin occludes one or more of the DCAF1
targeting domains without signiﬁcant structural perturbation. In
addition to – or instead of – direct competition of target recruit-
ment, Merlin’s binding may cause dramatic structural alterations,
thus attenuating DCAF1 targeting abilities. Further biochemical
studies and structural analyses will be paramount in gaining
mechanistic insight into Merlin’s inhibition of CRL4DCAF1.
5.3. Convergence on YAP and TAZ
The size of multicellular organisms and their composite tissues
is tightly regulated by restricting cell size and proliferation
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organ size throughout the animal kingdom. Notably, genetic exper-
iments in Drosophila and mice revealed that the Hippo pathway
controls cell proliferation and promotes apoptosis, and disruption
of the pathway at multiple levels leads to tissue overgrowth and
tumorigenesis [109,110]. This is particularly evident in mouse ge-
netic models, where dysregulation of Hippo pathway proteins in
the liver elicits dramatic hepatomegaly and development of a
range of tumors [24,111–114]. The Hippo pathway is canonically
driven by a core kinase cascade consisting of the Ste20-like kinases
Mst1 and Mst2 (Mst1/2), which in conjunction with Sav1, phos-
phorylate and activate the NDR family kinases Lats1 and Lats2
(Lats1/2) along with cofactors Mob1A and Mob1B. Active Lats ki-
nases phosphorylate and inactivate the YAP and TAZ transcrip-
tional coactivators (Fig. 2A). In the absence of Hippo signaling,
active YAP and TAZ translocate to the nucleus to promote tran-
scription of genes that drive proliferation, evasion of apoptosis,
and stemness [26,115]. The atypical cadherin Fat, along with the
apical polarity protein Crumbs, function in Drosophila to activate
the Hippo pathway. These proteins activate the FERM domain pro-
tein Expanded, which complexes with Merlin and Kibra to activate
the core kinase cascade [116–119]. Although the core kinase
cascade is evolutionarily conserved between Mammals and
Drosophila, the upstream signaling promoting activation of the
Hippo pathway has diverged.
It has recently become evident that some of the key proteins
regulating the core Hippo cascade in Drosophila evolved after the
divergence of arthropods. It is unclear whether Drosophila Ex-
panded (Ex) and Fat have orthologs in vertebrates, and the mam-
malian proteins which bare closest resemblance appear to
function primarily through Hippo-independent mechanisms
[120–123]. The adherens junction protein Echinoid and the uncon-
ventional myosin Dachs – a downstream target of Fat – regulate
the Drosophila Hippo pathway but are absent in vertebrates. Angi-
omotin was retained during the evolution of chordates as a regula-
tor of Hippo signaling but was replaced with Ex at the base of the
arthropod lineage [123]. The evolution of a novel domain in Ex to
bind Yki – the Drosophila ortholog of YAP – reestablished
Crumbs-mediated regulation of Hippo signaling which was uncou-
pled when the PDZ-binding motif of Yki was lost during arthropod
evolution. In addition to these evolutionary shifts in regulation of
Hippo signaling, Merlin’s input into the pathway appears to be
more complicated in mammals.
It is becomingly increasingly clear in mammals that multiple
signals converge to affect the Hippo core kinase cascade in addition
to canonical Hippo signaling [115]. Upstream of the core cassette,
Merlin can interact with Kibra to activate the Hippo kinase
cascade, although the biochemical mechanism is unclear
[24,117]. Merlin is recruited to tight junctions by Angiomotin,
which serves as a scaffold for PDZ- and WW-domain-containing
proteins, including Hippo pathway components (Fig. 2A)
[124–127]. Interestingly, tight junction-associated Angiomotin di-
rectly binds phosphorylated YAP and TAZ and retains them at the
cortex [124,127] and also serves as a scaffold for activation of the
Hippo core kinases Mst2 and Lats2, promoting canonical YAP/TAZ
inhibition [125]. Since Merlin binds to Angiomotin and displaces
other complexed proteins, it is plausible that Merlin’s binding
could modulate Angiomotin recruitment of Hippo components. It
remains to be tested whether Merlin promotes or inhibits Angi-
omotin’s direct effects on Hippo signaling. Recently it was found
that the p130 isoform of Angiomotin promotes YAP function by
disrupting its association with Lats1 in the cytoplasm, and further-
more, by binding to YAP in the nucleus to drive expression of a sub-
set of YAP target genes to drive tumorigenesis (Fig. 2A) [128]. It
will be of great interest to determine whether Angiomotin is
shuttled to the nucleus to promote YAP function in sparse cellsor cells that have had their tight junctions disrupted. Combined,
these results suggest Angiomotin has tumor suppressive and
growth-promoting functions, which may depend on the tissue, cel-
lular, or biochemical environment. Identiﬁcation of the contexts in
which Angiomotin functions to inhibit or promote Hippo signaling
– including the biochemical function of Merlin in these processes –
will provide important mechanistic insight into both Merlin func-
tion and Hippo signaling.
Drosophila genetics experiments provided strong evidence that
Merlin functions with Ex to activate Hippo signaling [25]. How-
ever, two recent landmark studies revealed separate, non-linear
mechanisms by which Merlin promotes Hippo signaling. DJ Pan’s
group found that Merlin could directly bind to Wts/Lats in both
Drosophila and mammals, recruiting these proteins to the plasma
membrane to be phosphorylated by active Mst1/2 (Fig. 2A) [129].
This study further used genetic experiments in mammalian cells
to show that Merlin promotes downstream Hippo signaling inde-
pendently of Mst1/2, revealing Merlin’s direct biochemical role in
regulating the Hippo pathway. More recently, however, our group
found that dysregulated CRL4DCAF1 promotes YAP function and
TEAD-dependent transcription by ubiquitinating and inhibiting
Lats1/2 in the nucleus (Fig. 2A) [130]. Genetic experiments and
analyses of Merlin mutations revealed that CRL4DCAF1-mediated
inhibition of Lats1/2 sustains the tumorigenicity of Merlin-deﬁ-
cient cells. Compellingly, analysis of clinical samples strongly sug-
gested that this YAP- and TAZ-promoting circuit of the Hippo
pathway functions in Merlin-deﬁcient malignancies. Furthermore,
our experiments revealed that tumor-derived Merlin mutants are
invariably defective in binding to CRL4DCAF1 yet retain Lats1 bind-
ing, providing genetic evidence that Merlin’s interaction with Lats1
at the plasma membrane is not sufﬁcient to suppress tumorigene-
sis. Merlin’s recruitment of Lats1 at the plasma membrane is an
important and evolutionarily conserved non-canonical Hippo
pathway mechanism. However, it appears that Merlin’s suppres-
sion of the CRL4DCAF1 E3 ubiquitin ligase is a paramount tumor sup-
pressive clamp embedded in the human Hippo pathway. In vivo
insight into the contribution of both of these mechanisms in mam-
mals will be an essential step in validating their signiﬁcance in the
context of normal function and tumorigenesis. These ﬁndings fur-
ther emphasize the lack of conservation between the linear model
for Hippo activation in Drosophila and the multifarious regulation
of YAP and TAZ in mammals. Combined, insights over the past ﬁve
years have shown that Merlin regulates the Hippo pathway at mul-
tiple levels, yet these signals invariably converge to regulate YAP
and TAZ activation [115]. As a next step, it will be important to
determine the spatio-temporal hierarchy of Merlin’s effects on
Hippo signaling and the importance of these pathways in patho-
genically relevant tissues, which may unmask the most signiﬁcant
druggable targets for Merlin-deﬁcient malignancies.
6. Conclusions
The biochemical mechanisms underlying Merlin-mediated
growth suppression are unraveling at an accelerating rate, with
several critical observations occurring within the past ﬁve years.
It is becoming increasingly clear that Merlin suppresses cell prolif-
eration through two modes that are deﬁned by functions at the
cortex or in the nucleus. By linking Par3 to a-catenin at adherens
junctions, Merlin promotes cell adhesions and thereby tissue orga-
nization in skin epithelium [59]. At tight junctions, Merlin’s
binding to Angiomotin releases Rich, which inactivates Rac and
thereby attenuates mitogenic signaling [7,28]. As Angiomotin di-
rectly suppresses Hippo signaling in the cytoplasm [124,125,127]
and promotes YAP activity in the nucleus [128], further insight is
needed to understand the contextual relevance of these
observations as well as how Merlin may be involved. Moreover,
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potential regulation of these pathways through interactions with
a-catenin warrants investigation. In contrast to Merlin’s cortex-
speciﬁc roles that largely inﬂuence cell junctions and Rac signaling,
intercellular and cortical cues lead to accumulation of dephospho-
rylated Merlin, which translocates to the nucleus and attenuates
oncogenic gene expression via inhibition of CRL4DCAF1 [29]. As
CRL4DCAF1 regulates several proteins that broadly control transcrip-
tion and epigenetics [98,104,105], Merlin is poised to dramatically
alter the expression of genes in response to adhesion signaling.
Furthermore, Merlin’s inhibition of CRL4DCAF1 prevents this E3 li-
gase from ubiquitinating and inhibiting the Lats kinases, maintain-
ing a clamp to restrict Hippo signaling to YAP [130]. Along with the
ﬁndings that Merlin recruits Lats1 at the plasma membrane to pro-
mote Hippo signaling, these recently discovered mechanisms link
Merlin to a pathway that has potent affects on cell proliferation,
stemness, and contact inhibition [1,115,129,130].
Recently, it was found that genetic ablation of Merlin promotes
drug resistance in melanoma, suggesting that loss of Merlin can
drive tumor evolution following initial cancer-causing oncogenic
insults [131]. This ﬁnding reiterates Merlin’s broad tumor suppres-
sive role and highlights the need to establish Merlin’s biochemical
functions in normal tissue and to delineate the vital pathways
dysregulated in Merlin-deﬁcient tumorigenesis. The signaling
pathways known to be regulated by Merlin lay as a cornerstone
for understanding Merlin’s functions in adhesion signaling and tu-
mor suppression. Research to deﬁne the importance and hierarchy
of these pathways, particularly in the pursuit of drugable targets in
Merlin-deﬁcient tumors, can be expected in the near future. While
in vivo models will be paramount in identifying and alleviating
pathogenic aberrations resulting from Merlin loss, biochemical
investigation – including full-length crystallographic analyses of
the inactive and active forms of Merlin – will simultaneously shed
light on Merlin’s normal function and guide the advent of therapies
targeting Merlin-deﬁcient malignancies.
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